Cision Vision introduces InVision, Vision Board
March 2025—Cision Vision has introduced its InVision imaging system and Vision Board. The technologies aim to enhance the efficiency and accuracy of lymph node dissections at the gross bench.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
FDA clears Thermo Fisher SARS-CoV-2, flu A/B, RSV test
March 2025—Thermo Fisher Scientific has received FDA 510(k) clearance for the Applied Biosystems TaqPath COVID-19, Flu A, Flu B, RSV Select Panel. The real-time PCR-based multiplex test covers the detection and differentiation of SARS-CoV-2, influenza A and B, and respiratory syncytial virus and enables the detection of co-infection. The panel runs on the Applied Biosystems QuantStudio 5 Dx real-time PCR system.
Q-linea nabs second contract in U.S. for ASTar instrument
March 2025—Q-linea announced that it has signed a second commercial contract for its ASTar instrumentation in the United States. Installation and training in a multihospital system will take place by the end of the first quarter this year. The quantitative antimicrobial susceptibility test system uses high-speed, time-lapse microscopy imaging of organisms in positive blood culture samples to determine the minimum inhibitory concentration of specific antimicrobial-organism combinations.
MRC Holland gets IVDR certification for HBOC syndrome assays
March 2025—MRC Holland announced that five of its SALSA MLPA assays for the detection of hereditary breast and ovarian cancer syndrome have been CE marked for in vitro diagnostic use under the EU in vitro diagnostic regulation 2017/746.
Labcorp test for advanced solid tumors now for clinical use
March 2025—Labcorp announced that its Labcorp Plasma Complete is now available for clinical use. The assay is a ctDNA-based comprehensive genomic profiling solution for patients with advanced solid tumors. It detects genomic alterations in circulating tumor DNA across 521 genes and covers established and emerging biomarkers associated with FDA-approved therapies, guideline-driven treatments, and clinical trial eligibility.
Tasso, ARUP partner to offer decentralized clinical research biomarker testing
March 2025—Tasso, a provider of clinical-grade blood collection solutions, and ARUP Laboratories announced they have entered into a partnership to develop and operationalize high-quality, at-home blood testing services to support clinical research.
BD to separate diagnostic business
March 2025—The BD board of directors authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD. The company says the aim is to enhance strategic focus and growth-oriented investments and capital allocation for BD and the separated business and to enhance value creation for shareholders. The decision was the result of a business portfolio evaluation, launched by BD in early 2024.
FDA clears Roche Elecsys sFlt-1/PlGF ratio for preeclampsia
March 2025—Roche announced that its Elecsys sFlt-1/PlGF ratio for preeclampsia has received FDA 510(k) clearance. The preeclampsia ratio supports the management of pregnant patients who have a singleton pregnancy and is intended to help clinicians stratify hospitalized patients into low- and high-risk categories for developing severe preeclampsia within two weeks of presentation.
FDA clears Roche Elecsys sFlt-1/PlGF ratio for preeclampsia
March 2025—Roche announced that its Elecsys sFlt-1/PlGF ratio for preeclampsia has received FDA 510(k) clearance. The preeclampsia ratio supports the management of pregnant patients who have a singleton pregnancy and is intended to help clinicians stratify hospitalized patients into low- and high-risk categories for developing severe preeclampsia within two weeks of presentation.
FDA clears Werfen Aptiva APS IgG, IgM reagents
February 2025—Werfen announced FDA 510(k) clearance for the Aptiva antiphospholipid syndrome immunoglobulin G and immunoglobulin M reagents. These immunoassay reagents use Aptiva’s particle-based multianalyte technology for the semiquantitative determination of anticardiolipin and anti-beta 2 glycoprotein 1 IgG and IgM in human serum and aid in diagnosing primary and secondary APS, when used in conjunction with other laboratory and clinical findings.